Navigation Links
Webcast Alert: MicroRNA: The Year in Review
Date:12/9/2009

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states, and therapeutic strategies based on microRNA modulation.


What:      MicroRNA: The Year in Review

When:      3 p.m. EST on Monday, December 14

Where:     http://www.videonewswire.com/event.asp?id=64631

How:       Live over the Internet -- Simply log on at the address above.


      Contact:

                      Regulus Therapeutics
                      Garry E. Menzel, Ph.D.
                      (760)268-6811

                      Media
                      Heidi Chokeir, Ph.D.
                      Russo Partners, LLC
                      (619)528-2217
                      heidi.chokeir@russopartnersllc.com

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from Alnylam Pharmaceuticals and Isis Pharmaceuticals (Alnylam and Isis jointly formed Regulus in 2007). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease and fibrosis, oncology, and immunology and inflammation. Regulus intellectual property estate contains both the fundamental and core patents in the field as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. For more information, visit www.regulusrx.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.

SOURCE Regulus Therapeutics Inc.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
2. Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications
3. Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
4. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Sunrise to Host Conference Call and Webcast to Discuss Third-Quarter 2009 Financial Results
7. Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday, November 4, at 10 A.M. EST
8. NHP Announces Third Quarter Earnings Release Date and Webcast/Conference Call
9. Smart Balance to Host Webcast/Conference Call on 2009 Third-Quarter Results
10. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results
11. CBIZ Webcasts Third-Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: